There was strong agreement between the proposed ensemble and clinical mFARS scores, reflected in a Pearson correlation of 0.81, Spearman's correlation of 0.76, R² of 0.46, RMSE of 10.30, and MAE of 8.79 on the unseen test set. Uncertainty was systematically evaluated using Uncertainty Characteristics Curves (UCC), where the ensemble achieved an Area Under UCC (AUUCC) of 8.83.
Monday, October 20, 2025
A Probabilistic Deep Ensemble Framework for the Objective Assessment of Friedreich Ataxia
Maneesha Randeniya, Kanishka Ranaweera, Thang Ngo, et al. A Probabilistic Deep Ensemble Framework for the Objective Assessment of Friedreich Ataxia. TechRxiv. October 16, 2025. DOI: 10.36227/techrxiv.176062677.75204670/v1
Chapter 23 - Omaveloxolone: a nuclear factor erythroid 2-related factor 2 activator for Friedreich’s ataxia
Ziquan Zhao, Junjie Wang, Mengchen Lu, Qidong You, Zhengyu Jiang, Chapter 23 - Omaveloxolone: a nuclear factor erythroid 2-related factor 2 activator for Friedreich’s ataxia, Editor(s): Bin Yu, Peng Zhan, Drug Discovery Stories, Volume 2, Elsevier,
2026, Pages 331-344, ISBN 9780443338854, doi:10.1016/B978-0-443-33885-4.00038-X.
Nuclear factor erythroid 2-related factor 2 (NRF2) is an important cytoprotective transcription factor that affects the fate of the cell. Impairment of the NRF2 signaling pathway has been regarded as a major contributor to the pathophysiology of FRDA, and targeting NRF2 activation has become an attractive strategy for the treatment of FRDA.
Subscribe to:
Comments (Atom)
